Spero Therapeutics (SPRO) Insider Trading & Ownership $2.17 -0.09 (-3.98%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$2.16 0.00 (-0.23%) As of 08/7/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Spero Therapeutics (NASDAQ:SPRO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage5.50%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$205.98K Get SPRO Insider Trade Alerts Want to know when executives and insiders are buying or selling Spero Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address SPRO Insider Buying and Selling by Quarter Spero Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails2/5/2025Ankit MahadeviaDirectorSell69,219$0.78$53,990.82 2/5/2025Esther RajaveluCFOSell20,689$0.78$16,137.42 2/5/2025Sath ShuklaCEOSell155,333$0.78$121,159.74 8/27/2024Ankit MahadeviaDirectorSell5,912$1.35$7,981.20 8/27/2024Sath ShuklaCEOSell2,757$1.35$3,721.95 8/27/2024Timothy KeutzerCOOSell2,213$1.35$2,987.55 (Data available from 1/1/2013 forward) SPRO Insider Trading Activity - Frequently Asked Questions Who is on Spero Therapeutics' Insider Roster? The list of insiders at Spero Therapeutics includes Ankit Mahadevia, Aquilo Capital Management, Llc, Esther Rajavelu, Kamal Hamed, Sath Shukla, and Timothy Keutzer. Learn more on insiders at SPRO. What percentage of Spero Therapeutics stock is owned by insiders? 5.50% of Spero Therapeutics stock is owned by insiders. Learn more on SPRO's insider holdings. Which Spero Therapeutics insiders have been selling company stock? The following insiders have sold SPRO shares in the last 24 months: Ankit Mahadevia ($73,362.42), Esther Rajavelu ($16,137.42), Kamal Hamed ($50,159.92), Sath Shukla ($172,939.30), and Timothy Keutzer ($5,323.59). How much insider selling is happening at Spero Therapeutics? Insiders have sold a total of 343,117 Spero Therapeutics shares in the last 24 months for a total of $317,922.65 sold. Spero Therapeutics Key ExecutivesDr. Ankit Mahadevia M.D. (Age 43)MBA, Co-Founder & Chairman of the Board Compensation: $1.39MMr. Satyavrat Shukla C.F.A. (Age 51)President, CEO & Director Compensation: $1.12MMr. Timothy Keutzer (Age 56)Chief Operating Officer Compensation: $938.57kMs. Esther P. Rajavelu (Age 45)CFO, Chief Business Officer & Treasurer Mr. James P. BradyChief Human Resource OfficerDr. Kamal Hamed M.B.A. (Age 63)M.D., M.P.H., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies aTyr Pharma Insider Trades Tourmaline Bio Insider Trades Erasca Insider Trades MBX Biosciences Insider Trades Cullinan Therapeutics Insider Trades Kodiak Sciences Insider Trades Precigen Insider Trades REGENXBIO Insider Trades Savara Insider Trades Compass Therapeutics Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Strategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying3 Catalysts Driving Plug Power’s Turnaround CaseInsider Selling Hits Market Leaders—Should You Be Worried?Insiders Spent Millions on These 3 Stocks Over the Past 2 Months This page (NASDAQ:SPRO) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
